BMY

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN NVS

| Held by: VTI SCHD VOO SPY IVV VTV XLV JEPI COWZ VYM

Index	S&P 500	P/E	18.64	EPS (ttm)	2.48	Insider Own	0.06%	Shs Outstand	2.04B	Perf Week	-1.99%
Market Cap	94.04B	Forward P/E	7.66	EPS next Y	6.03	Insider Trans	-4.10%	Shs Float	2.03B	Perf Month	-3.45%
Enterprise Value	131.40B	PEG	0.26	EPS next Q	1.69	Inst Own	82.26%	Short Float	1.53%	Perf Quarter	-8.86%
Income	5.05B	P/S	1.97	EPS this Y	466.40%	Inst Trans	0.72%	Short Ratio	2.51	Perf Half Y	-23.36%
Sales	47.70B	P/B	5.39	EPS next Y	-7.41%	ROA	5.33%	Short Interest	31.19M	Perf YTD	-18.32%
Book/sh	8.57	P/C	6.91	EPS next 5Y	72.10%	ROE	29.31%	52W High	63.33 -27.05%	Perf Year	-6.25%
Cash/sh	6.69	P/FCF	6.45	EPS past 3/5Y	- -	ROIC	7.96%	52W Low	42.96 7.54%	Perf 3Y	-32.81%
Dividend Est.	2.48 (5.36%)	EV/EBITDA	6.93	Sales past 3/5Y	1.36% 13.06%	Gross Margin	61.74%	Volatility	2.19% 1.98%	Perf 5Y	-22.94%
Dividend TTM	2.46 (5.32%)	EV/Sales	2.75	EPS Y/Y TTM	176.42%	Oper. Margin	26.11%	ATR (14)	1.04	Perf 10Y	-21.36%
Dividend Ex-Date	Jul 03, 2025	Quick Ratio	1.11	Sales Y/Y TTM	2.57%	Profit Margin	10.58%	RSI (14)	43.16	Recom	2.66
Dividend Gr. 3/5Y	6.38% 7.57%	Current Ratio	1.21	EPS Q/Q	-22.37%	SMA20	-2.65%	Beta	0.35	Target Price	52.35
Payout	-	Debt/Eq	2.92	Sales Q/Q	0.56%	SMA50	-1.85%	Rel Volume	0.96	Prev Close	47.54
Employees	34100	LT Debt/Eq	2.64	Earnings	Jul 31 BMO	SMA200	-11.94%	Avg Volume	12.42M	Price	46.20
IPO	Jul 05, 1929	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.79% 7.21%	Trades		Volume	11,889,953	Change	-2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-25	Downgrade	Daiwa Securities	Outperform → Neutral	$42
Apr-22-25	Initiated	Piper Sandler	Overweight
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$55
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55
Nov-09-23	Initiated	Deutsche Bank	Hold	$55
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral	$68 → $54
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold	$55 → $53
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$60

Show Previous Ratings

Sep-12-25 10:25AM	Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects (Zacks)
09:08AM	BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? (Zacks)
09:00AM	Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
03:00AM	Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl (Barrons.com)
12:03AM	3 Reasons to Sell BMY and 1 Stock to Buy Instead (StockStory)
01:01PM	Loading…
Sep-11-25 01:01PM	Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer (Insider Monkey)
12:49PM	BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY) (Insider Monkey)
10:01AM	Prothena Down 40% Year to Date: What Lies Ahead for the Stock? (Zacks)
09:52AM	Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? (Zacks)
06:30AM	Chinas Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington (The Daily Upside)
Sep-10-25 05:20AM	Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52% (Insider Monkey)
Sep-09-25 05:45PM	Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know (Zacks)
01:17PM	SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study (Zacks)
10:15AM	Idiopathic pulmonary fibrosis breakthroughs may lead to first drug approval in years (Clinical Trials Arena)
06:05AM	The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now (Motley Fool)
09:42AM	Loading…
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
Sep-05-25 06:20AM	Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug (BioPharma Dive)
Sep-04-25 10:30AM	TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock? (Zacks)
07:53AM	2 Top Dividend Stocks to Buy With Less Than $50 (Motley Fool)
03:13AM	How Is Bristol-Myers Stock Performance Compared to Other Pharma Stocks? (Barchart)
Sep-03-25 10:02AM	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results (Zacks)
Sep-02-25 11:09AM	Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows. (Barrons.com)
10:10AM	Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth? (Zacks)
03:29AM	Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital (Insider Monkey)
Sep-01-25 09:00AM	Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Aug-31-25 12:10AM	BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY) (Insider Monkey)
Aug-30-25 03:18AM	Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease (Investor's Business Daily)
Aug-29-25 06:59AM	Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-28-25 12:48AM	Cantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral (Insider Monkey)
Aug-27-25 10:05AM	Will Camzyos Strengthen BMY's Cardiovascular Portfolio? (Zacks)
11:32PM	Loading…
Aug-26-25 11:32PM	Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY) (StockStory)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
06:59AM	Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025 (Business Wire)
Aug-22-25 11:11AM	BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now? (Zacks)
Aug-20-25 09:52AM	Does Cobenfy Have the Potential to Become a Top Drug for BMY? (Zacks)
08:00AM	Supply-Chain Tech Firm Overhaul Raises $105 Million (The Wall Street Journal)
07:15AM	FDA awards breakthrough therapy status to BMS and SystImmunes NSCLC drug (Pharmaceutical Technology)
Aug-19-25 09:08AM	Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue? (Zacks)
09:00AM	Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know (Zacks)
Aug-18-25 06:36AM	The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific (Zacks)
06:00AM	Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer (PR Newswire)
03:58AM	Biopharma layoffs rise as drugmakers tighten belts and reorganize (Pharma Voice)
Aug-17-25 03:18AM	Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies (Insider Monkey)
Aug-15-25 08:10PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
04:55PM	Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology (Zacks)
10:00AM	AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs (Zacks)
08:48AM	Big Pharma Has a New Vision for Selling Drugs. It's Going to the Mattresses. (Barrons.com)
Aug-14-25 09:11AM	Exelixis Gains 15.6% YTD: How Should You Play the Stock? (Zacks)
Aug-13-25 12:55PM	PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last? (Zacks)
08:52AM	Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? (Zacks)
08:36AM	Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition? (Zacks)
06:26AM	Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks (Motley Fool)
12:25AM	Bristol-Myers Squibb's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
12:00AM	BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook (StockStory)
Aug-12-25 04:01PM	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire)
07:00AM	X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership (GlobeNewswire)
06:59AM	Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda (GlobeNewswire)
02:57AM	Puerto Ricos ongoing journey from manufacturing hub to innovation enterprise (Pharma Voice)
Aug-11-25 05:38AM	Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 \| Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth (GlobeNewswire)
05:13AM	Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 \| J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations (GlobeNewswire)
02:00AM	Gilead Stock Is Closing In on an All-Time High. The Case for More Upside. (Barrons.com)
02:00AM	Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. (Barrons.com)
Aug-08-25 11:52PM	Jim Cramer on Bristol-Myers: "Have Not Been Recommending the Stock" (Insider Monkey)
Aug-06-25 09:18AM	BMY Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
08:31AM	5% Yields Are Hard to Find. Here Are 4 Dividend Stocks You Can Count On. (Barrons.com)
06:30AM	Pfizer Pops Despite Looming Pharma Tariffs (The Daily Upside)
Aug-05-25 11:47AM	Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth (Zacks)
09:10AM	Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? (Zacks)
09:00AM	Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:17AM	Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO (BioPharma Dive)
Aug-04-25 04:16PM	Bristol Myers Squibbs Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) (Business Wire)
10:14AM	BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. (Barrons.com)
08:51AM	J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal? (Zacks)
08:30AM	Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas (PR Newswire)
06:45AM	BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-03-25 10:00AM	Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time (The Wall Street Journal)
Aug-02-25 07:48AM	Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu (Insider Monkey)
Aug-01-25 07:32PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
07:10AM	Regeneron cancer bispecific rejected again; Allogene discloses trial death (BioPharma Dive)
Jul-31-25 11:32PM	Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025 (Insider Monkey) -5.81%
06:31PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
05:25PM	Trump Talks Tough on Drug Prices but His Demands Have Softened (Barrons.com)
04:16PM	What Trump's Big Pharma CEO letters mean for drug pricing power (Yahoo Finance Video)
02:30PM	Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs (The Wall Street Journal)
01:40PM	Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today (StockStory)
12:18PM	Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook (Yahoo Finance Video)
11:43AM	Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View (Zacks)
11:08AM	PCE Comes in Warmer Than Expected (Zacks)
11:01AM	Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic (StockStory)
10:44AM	Economy Heating Up on PCE for June (Zacks)
10:42AM	Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion (Benzinga)
10:02AM	Is Wall Street Bullish or Bearish on Bristol-Myers Stock? (Barchart)
09:30AM	Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates (Zacks)
07:48AM	Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio (Investing.com)
07:18AM	Bristol Myers: Q2 Earnings Snapshot (Associated Press Finance)
07:10AM	Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations (The Wall Street Journal)
07:01AM	Bristol Myers posts better-than-expected second quarter results on strength of top sellers (Reuters)
06:59AM	Bristol Myers Squibb Reports Second Quarter Financial Results for 2025 (Business Wire)
06:59AM	Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. (Barrons.com)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elkins David V	EVP, Chief Financial Officer	Sep 02 '25	Sale	47.33	56,000	2,650,480	167,379	Sep 03 06:46 PM
Short Bartie Wendy	EVP, Corporate Affairs	Sep 01 '25	Option Exercise	0.00	1,235	0	6,301	Sep 03 06:42 PM
Elkins David V	Officer	Sep 02 '25	Proposed Sale	47.30	56,000	2,648,800		Sep 02 11:16 AM
Gallman Cari	EVP, General Counsel	Aug 01 '25	Option Exercise	0.00	1,061	0	9,383	Aug 05 06:01 PM
Short Bartie Wendy	EVP, Corporate Affairs	Aug 02 '25	Option Exercise	0.00	738	0	5,444	Aug 05 05:58 PM
Short Bartie Wendy	EVP, Corporate Affairs	Aug 02 '25	Sale	44.23	378	16,719	5,066	Aug 05 05:58 PM
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '25	Option Exercise	0.00	8,040	0	8,040	Jun 04 05:37 PM
Hickey Benjamin	President, RayzeBio Org.	May 09 '25	Sale	38.01	97	3,702	0	May 13 07:03 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Apr 25 '25	Buy	47.58	4,250	202,215	83,513	Apr 29 06:14 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '25	Option Exercise	0.00	3,306	0	15,489	Apr 03 05:15 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '25	Option Exercise	0.00	11,255	0	20,148	Mar 12 09:39 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '25	Option Exercise	0.00	23,150	0	26,937	Mar 12 09:37 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Mar 10 '25	Option Exercise	0.00	20,423	0	22,339	Mar 12 09:35 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '25	Option Exercise	0.00	16,684	0	20,017	Mar 12 09:34 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '25	Option Exercise	0.00	7,164	0	8,546	Mar 12 09:32 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '25	Option Exercise	0.00	48,718	0	386,496	Mar 12 09:32 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '25	Option Exercise	0.00	7,446	0	7,920	Mar 12 09:31 PM
Holzer Phil M	SVP and Controller	Mar 10 '25	Option Exercise	0.00	7,140	0	17,870	Mar 12 09:31 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '25	Option Exercise	0.00	44,098	0	99,040	Mar 12 09:30 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '25	Option Exercise	0.00	7,588	0	11,626	Mar 12 09:29 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '25	Option Exercise	0.00	69,517	0	252,608	Mar 12 09:28 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '25	Option Exercise	0.00	60,034	0	152,898	Mar 12 09:27 PM
Hickey Benjamin	President, RayzeBio Org.	Mar 01 '25	Option Exercise	0.00	3,286	0	10,419	Mar 04 05:44 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Feb 20 '25	Buy	55.05	2,000	110,096	104,626	Feb 21 07:09 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Feb 14 '25	Buy	54.84	1,823	100,000	63,932	Feb 19 07:19 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '25	Option Exercise	0.00	10,078	0	10,858	Feb 04 07:05 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '25	Option Exercise	0.00	2,543	0	7,829	Feb 04 07:04 PM
Holzer Phil M	SVP and Controller	Nov 04 '24	Sale	55.62	700	38,930	11,760	Nov 05 05:53 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '24	Option Exercise	0.00	2,964	0	104,169	Nov 05 05:42 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Nov 01 '24	Buy	54.67	1,830	100,055	62,109	Nov 05 05:41 PM
Holzer Phil M	Officer	Nov 04 '24	Proposed Sale	55.62	700	38,930		Nov 04 11:20 AM
Gallman Cari	EVP, Corporate Affairs	Oct 02 '24	Option Exercise	0.00	4,558	0	6,667	Oct 03 06:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bristol-Myers Squibb Co

Upgrade your FINVIZ experience